Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Comparison of HHV-6 DNA detection in plasma and whole blood in allogeneic hematopoietic stem cell transplant recipients: frequent false-positive results for active HHV-6 infection using whole blood samples.

Takano K, Ogata M, Kawano R, Satou T, Nashimoto Y, Shirao K.

Int J Hematol. 2018 Jul 16. doi: 10.1007/s12185-018-2498-z. [Epub ahead of print]

PMID:
30014227
2.

[Successful treatment of secondary graft failure in a mixed-phenotype acute leukemia patient with haploidentical hematopoietic stem cell transplantation and post-transplant cyclophosphamide administration].

Katayama O, Honda S, Yoshida N, Nagamatsu K, Takano K, Kawano R, Ogata M, Shirao K.

Rinsho Ketsueki. 2018;59(5):485-488. doi: 10.11406/rinketsu.59.485. Japanese.

PMID:
29877234
3.

Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorder, Hodgkin Type, following Epstein-Barr Viral Hepatitis in a Patient with Rheumatoid Arthritis.

Saburi M, Ogata M, Yoshida N, Nashimoto Y, Moroga Y, Takano K, Kohno K, Daa T, Shirao K.

Intern Med. 2018 Apr 15;57(8):1145-1149. doi: 10.2169/internalmedicine.9599-17. Epub 2017 Dec 27.

4.

Hemophagocytic lymphohistiocytosis following influenza vaccination in a patient with aplastic anemia undergoing allogeneic bone marrow stem cell transplantation.

Ikebe T, Takata H, Sasaki H, Miyazaki Y, Ohtsuka E, Saburi Y, Ogata M, Shirao K.

Int J Hematol. 2017 Apr;105(4):389-391. doi: 10.1007/s12185-016-2177-x. Epub 2017 Jan 4. No abstract available.

PMID:
28054244
5.

Successful Cord Blood Stem Cell Transplantation for an Adult Case of Chronic Active Epstein-Barr Virus Infection.

Saburi M, Ogata M, Satou T, Yoshida N, Nagamatsu K, Nashimoto Y, Moroga Y, Takano K, Kohno K, Shirao K.

Intern Med. 2016;55(23):3499-3504. Epub 2016 Dec 1.

6.

Toxoplasmic Encephalitis with Untreated Hairy Cell Leukemia Variant.

Ikebe T, Sasaki H, Takata H, Miyazaki Y, Ohtsuka E, Saburi Y, Ogata M, Shirao K.

Intern Med. 2016;55(21):3175-3180. Epub 2016 Nov 1.

7.

Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells.

Hirashita Y, Tsukamoto Y, Yanagihara K, Fumoto S, Hijiya N, Nakada C, Uchida T, Matsuura K, Kodama M, Okimoto T, Daa T, Seike M, Iha H, Shirao K, Murakami K, Moriyama M.

Cancer Sci. 2016 Dec;107(12):1919-1928. doi: 10.1111/cas.13094. Epub 2016 Dec 19.

8.

Optimal step-down approach for pediatric asthma controlled by salmeterol/fluticasone: A randomized, controlled trial (OSCAR study).

Akashi K, Mezawa H, Tabata Y, Atsuta J, Tokuda R, Kawada Y, Kitamura T, Murasugi H, Ito H, Tabata M, Shirao K, Sato S, Nishimura H, Fujiwara M, Masuda K, Arakawa H, Adachi Y, Yoshihara S, Fujisawa T, Katsunuma T.

Allergol Int. 2016 Jul;65(3):306-11. doi: 10.1016/j.alit.2016.02.010. Epub 2016 May 4.

9.

Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone.

Takata H, Ikebe T, Sasaki H, Miyazaki Y, Ohtsuka E, Saburi Y, Ogata M, Shirao K.

Intern Med. 2016;55(9):1177-81. doi: 10.2169/internalmedicine.55.5223. Epub 2016 May 1.

10.

Significance of ACADM mutations identified through newborn screening of MCAD deficiency in Japan.

Hara K, Tajima G, Okada S, Tsumura M, Kagawa R, Shirao K, Ohno Y, Yasunaga S, Ohtsubo M, Hata I, Sakura N, Shigematsu Y, Takihara Y, Kobayashi M.

Mol Genet Metab. 2016 May;118(1):9-14. doi: 10.1016/j.ymgme.2015.12.011. Epub 2015 Dec 29.

PMID:
26947917
11.

Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma.

Hijiya N, Tsukamoto Y, Nakada C, Tung Nguyen L, Kai T, Matsuura K, Shibata K, Inomata M, Uchida T, Tokunaga A, Amada K, Shirao K, Yamada Y, Mori H, Takeuchi I, Seto M, Aoki M, Takekawa M, Moriyama M.

Cancer Res. 2016 May 1;76(9):2612-25. doi: 10.1158/0008-5472.CAN-15-1846. Epub 2016 Mar 3.

12.

Bevacizumab safety in Japanese patients with colorectal cancer.

Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K.

Jpn J Clin Oncol. 2016 Mar;46(3):234-40. doi: 10.1093/jjco/hyv182. Epub 2016 Jan 15.

PMID:
26774113
13.

Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method.

Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T, Doi T, Takahashi A, Odaka Y, Okuyama M, Sawada J, Sakamoto H, Yoshida T.

BMC Cancer. 2015 Oct 16;15:718. doi: 10.1186/s12885-015-1721-z.

14.

Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).

Nishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K, Mizusawa J, Nakamura K, Shirao K, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group.

Gastric Cancer. 2016 Jul;19(3):902-10. doi: 10.1007/s10120-015-0542-8. Epub 2015 Sep 19.

PMID:
26386560
15.

[Hypofibrinogenemia associated with steroid therapy for the patients who developed GVHD after allogeneic stem cell transplantation].

Moroga Y, Takata H, Yoshida N, Nagamatsu K, Nashimoto Y, Saburi M, Takano K, Ikebe T, Kohno K, Ogata M, Shirao K.

Rinsho Ketsueki. 2015 Jul;56(7):883-8. doi: 10.11406/rinketsu.56.883. Japanese.

PMID:
26251153
16.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).

Yoshida M, Muro K, Tsuji A, Hamamoto Y, Yoshino T, Yoshida K, Shirao K, Miyata Y, Takahari D, Takahashi T, Ohtsu A.

Eur J Cancer. 2015 May;51(8):935-41. doi: 10.1016/j.ejca.2015.03.007. Epub 2015 Mar 30.

17.

[S-1 plus cisplatin(SP) for advanced gastric cancer].

Nishikawa K, Watanabe K, Shirao K.

Nihon Rinsho. 2015 Feb;73 Suppl 2:572-6. Japanese. No abstract available.

PMID:
25831825
18.

Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.

Oh DY, Doi T, Shirao K, Lee KW, Park SR, Chen Y, Yang L, Valota O, Bang YJ.

Cancer Res Treat. 2015 Oct;47(4):687-96. doi: 10.4143/crt.2014.225. Epub 2015 Feb 12.

19.

A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.

Yamazaki K, Kuwano H, Ojima H, Otsuji T, Kato T, Shimada K, Hyodo I, Nishina T, Shirao K, Esaki T, Ohishi T, Denda T, Takeuchi M, Boku N.

Cancer Chemother Pharmacol. 2015 Mar;75(3):569-77. doi: 10.1007/s00280-015-2676-0. Epub 2015 Jan 10.

PMID:
25575764
20.

Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab.

Otsu S, Hirashima Y, Nishikawa K, Sakashita H, Morinaga R, Watanabe K, Shirao K.

Jpn Clin Med. 2014 Aug 12;5:19-23. doi: 10.4137/JCM.S15553. eCollection 2014.

21.

Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.

Sasaki Y, Hamaguchi T, Arai T, Goto A, Ura T, Muro K, Yamada Y, Shirao K, Shimada Y.

Anticancer Res. 2014 Apr;34(4):2029-34.

PMID:
24692743
22.

Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.

Takashima A, Boku N, Kato K, Nakamura K, Mizusawa J, Fukuda H, Shirao K, Shimada Y, Ohtsu A.

Gastric Cancer. 2014;17(3):522-8. doi: 10.1007/s10120-013-0309-z. Epub 2013 Oct 26.

PMID:
24162387
23.

Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).

Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, Fukuda H, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2013 Oct;43(10):972-80. doi: 10.1093/jjco/hyt114. Epub 2013 Sep 7.

PMID:
24014884
24.

CD34-negative solitary fibrous tumour resistant to imatinib.

Watanabe K, Otsu S, Morinaga R, Shirao K.

BMJ Case Rep. 2013 Jul 5;2013. pii: bcr2013200126. doi: 10.1136/bcr-2013-200126.

25.

Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.

Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T, Takahashi A, Odaka Y, Okuyama M, Sawada J, Sakamoto H, Yoshida T.

J Biosci Bioeng. 2013 Dec;116(6):768-73. doi: 10.1016/j.jbiosc.2013.05.021. Epub 2013 Jun 29.

PMID:
23816762
26.

Identification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer.

Sakashita H, Inoue H, Akamine S, Ishida T, Inase N, Shirao K, Mori M, Mimori K.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S590-8. doi: 10.1245/s10434-013-3059-6. Epub 2013 Jun 28. Erratum in: Ann Surg Oncol. 2014 Dec;21 Suppl 4:S783.

PMID:
23812770
27.

Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.

Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, Konishi M, Yasui H, Terashima M, Goto M, Tanigawa N, Shirao K, Sano T, Sasako M.

Gastric Cancer. 2014 Apr;17(2):383-6. doi: 10.1007/s10120-013-0264-8. Epub 2013 May 30.

PMID:
23719867
28.

"Bitter sweet": a child case of erythritol-induced anaphylaxis.

Shirao K, Inoue M, Tokuda R, Nagao M, Yamaguchi M, Okahata H, Fujisawa T.

Allergol Int. 2013 Jun;62(2):269-71. doi: 10.2332/allergolint.12-LE-0517. Epub 2013 Apr 25. No abstract available.

29.

[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].

Hirashima Y, Shirao K.

Gan To Kagaku Ryoho. 2012 Nov;39(11):1603-7. Japanese.

PMID:
23152010
30.

Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.

Doi T, Hamaguchi T, Shirao K, Chin K, Hatake K, Noguchi K, Otsuki T, Mehta A, Ohtsu A.

Int J Clin Oncol. 2013 Feb;18(1):87-95. doi: 10.1007/s10147-011-0348-6. Epub 2012 Jan 11.

PMID:
22234637
31.

Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial.

Tanai C, Nakajima TE, Nagashima K, Kato K, Hamaguchi T, Yamada Y, Muro K, Shirao K, Kunitoh H, Matsumura Y, Yamamoto S, Shimada Y.

J Oncol Pract. 2011 May;7(3):148-53. doi: 10.1200/JOP.2010.000106.

32.

Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.

Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Takashima A, Okita N, Takahari D, Nakajima T, Hamaguchi T, Shimada Y, Shirao K.

Int J Cancer. 2012 May 15;130(10):2359-65. doi: 10.1002/ijc.26282. Epub 2011 Nov 28.

33.

Ectopic hepatocellular carcinoma of the left sub-diaphragm with metastasis.

Nishikawa K, Watanabe K, Hisamatsu Y, Shirao K.

Intern Med. 2011;50(14):1505-6. Epub 2011 Jul 15. No abstract available.

34.

A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).

Hamaguchi T, Shirao K, Ohtsu A, Hyodo I, Arai Y, Takiuchi H, Fujii H, Yoshida M, Saito H, Denda T, Koizumi W, Iwase H, Boku N; Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group.

Gastric Cancer. 2011 Aug;14(3):226-33. doi: 10.1007/s10120-011-0030-8. Epub 2011 Apr 19.

PMID:
21503598
35.

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.

Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y, Taniguchi H, Shirao K.

Gastric Cancer. 2011 Jun;14(2):161-5. doi: 10.1007/s10120-011-0025-5. Epub 2011 Feb 16.

PMID:
21327441
36.

Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report.

Watanabe K, Otsu S, Morinaga R, Kawano S, Hirashima Y, Sakashita H, Shirao K.

BMC Gastroenterol. 2010 Nov 1;10:128. doi: 10.1186/1471-230X-10-128.

37.

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.

Takahari D, Shimada Y, Takeshita S, Nishitani H, Takashima A, Okita N, Hirashima Y, Kato K, Hamaguchi T, Yamada Y, Shirao K.

Gastric Cancer. 2010 Aug;13(3):186-90. doi: 10.1007/s10120-010-0557-0. Epub 2010 Sep 5.

PMID:
20820988
38.

A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.

Kato K, Inaba Y, Tsuji Y, Esaki T, Yoshioka A, Mizunuma N, Mizuno T, Kusaba H, Fujii H, Muro K, Shimada Y, Shirao K.

Jpn J Clin Oncol. 2011 Jan;41(1):63-8. doi: 10.1093/jjco/hyq158. Epub 2010 Sep 6.

PMID:
20819832
39.

Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer.

Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, Kinoshita T, Yasui H, Terashima M, Goto M, Tanigawa N, Shirao K, Sano T, Sasako M.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1423-8. doi: 10.1007/s00280-010-1432-8. Epub 2010 Sep 1.

PMID:
20809123
40.

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki-Mogami T, Naito M, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Tamura T, Yamada Y, Ohe Y, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Okuda H.

Br J Clin Pharmacol. 2010 Aug;70(2):222-33. doi: 10.1111/j.1365-2125.2010.03695.x.

41.

Evaluation of mandibular condylar movement exercise for patients with internal derangement of the temporomandibular joint on initial presentation.

Yoshida H, Sakata T, Hayashi T, Shirao K, Oshiro N, Morita S.

Br J Oral Maxillofac Surg. 2011 Jun;49(4):310-3. doi: 10.1016/j.bjoms.2010.05.016. Epub 2010 Jul 13.

PMID:
20630631
42.

Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC).

Hamaguchi T, Shirao K, Moriya Y, Yoshida S, Kodaira S, Ohashi Y; NSAS-CC Group.

Cancer Chemother Pharmacol. 2011 Mar;67(3):587-96. doi: 10.1007/s00280-010-1358-1. Epub 2010 May 19.

PMID:
20490797
43.

Molecular pathogenesis of a novel mutation, G108D, in short-chain acyl-CoA dehydrogenase identified in subjects with short-chain acyl-CoA dehydrogenase deficiency.

Shirao K, Okada S, Tajima G, Tsumura M, Hara K, Yasunaga S, Ohtsubo M, Hata I, Sakura N, Shigematsu Y, Takihara Y, Kobayashi M.

Hum Genet. 2010 Jun;127(6):619-28. doi: 10.1007/s00439-010-0822-7. Epub 2010 Apr 8. Review.

PMID:
20376488
44.

[Standard chemotherapy of solid tumors. 2) Cancers of the digestive system].

Sakashita H, Shirao K.

Nihon Naika Gakkai Zasshi. 2009 Aug 10;98(8):1866-73. Review. Japanese. No abstract available.

PMID:
19891104
45.

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group.

Lancet Oncol. 2009 Nov;10(11):1063-9. doi: 10.1016/S1470-2045(09)70259-1. Epub 2009 Oct 7.

PMID:
19818685
46.

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.

Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H.

Cancer Chemother Pharmacol. 2010 May;66(1):95-105. doi: 10.1007/s00280-009-1138-y. Epub 2009 Sep 22.

PMID:
19771428
47.

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.

Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A.

Invest New Drugs. 2010 Dec;28(6):866-75. doi: 10.1007/s10637-009-9306-9.

PMID:
19730791
48.

Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.

Takashima A, Shirao K, Hirashima Y, Takahari D, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y.

J Cancer Res Clin Oncol. 2010 Feb;136(2):243-8. doi: 10.1007/s00432-009-0655-8.

PMID:
19727819
49.

Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.

Doi T, Ohtsu A, Tahara M, Tamura T, Shirao K, Yamada Y, Otani S, Yang BB, Ohkura M, Ohtsu T.

Int J Clin Oncol. 2009 Aug;14(4):307-14. doi: 10.1007/s10147-008-0855-2. Epub 2009 Aug 25.

PMID:
19705240
50.

Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.

Okita NT, Yamada Y, Takahari D, Hirashima Y, Matsubara J, Kato K, Hamaguchi T, Shirao K, Shimada Y, Taniguchi H, Shimoda T.

Jpn J Clin Oncol. 2009 Sep;39(9):595-600. doi: 10.1093/jjco/hyp066. Epub 2009 Jun 17.

PMID:
19535387

Supplemental Content

Loading ...
Support Center